What process is Zicam currently taking to respond to the FDA and share its research data?
Zicam’s manufacturer, Matrixx Initiatives, is heading the FDA’s request to respond to the consumer warning letter by July 22 to outline the company’s plans to cease marketing the cited products. We are formulating our full response and intend to meet with this regulatory body to resolve this matter by sharing all of our safety and efficacy research as soon as possible. We are confident in the depth of our science and safety data.
Related Questions
- I’d like to share the data I’ve collected with ASQ-3 with the authors to help further their research and the development of future editions. How do I do that?
- I’d like to share the data I’ve collected with ASQ:SE with the authors to help further their research and the development of future editions. How do I do that?
- What process is Zicam currently taking to respond to the FDA and share its research data?
